Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response

Journal of General Virology

Volumn 98, Issue 5, 2017, Pages 946-954

  Cheung, Nam Nam ^a   Lai, Kin Kui ^a   Dai, Jun ^a   Kok, Kin Hang ^a   Chen, Honglin ^a,b   Chan, Kwok Hung ^a   Yuen, Kwok Yung ^a,b   Tsun Kao, Richard Yi ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Broad spectrum antivirals; Influenza; Pyrimidine synthesis inhibitor; Respiratory tract infections

Indexed keywords

ANTIVIRUS AGENT; FA 613; UNCLASSIFIED DRUG; DIHYDROOROTATE DEHYDROGENASE; ENZYME INHIBITOR; INTERFERON; OXIDOREDUCTASE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENTEROVIRUS A71; GENE REPLICATION; GENETIC TRANSCRIPTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMAN RHINOVIRUS A; IMMUNE RESPONSE; INFLUENZA A (H5N1); INFLUENZA A (H7N9); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H7N9); MDCK CELL LINE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; RNA VIRUS; SARS CORONAVIRUS; TREATMENT RESPONSE; VERO CELL LINE; VIRUS GENOME; VIRUS INHIBITION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; SURVIVAL ANALYSIS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; ENZYME INHIBITORS; HUMANS; INTERFERONS; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; ORTHOMYXOVIRIDAE INFECTIONS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PYRIMIDINES; RNA VIRUSES; SURVIVAL ANALYSIS;

EID: 85020424801     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/jgv.0.000758     Document Type: Article

References (33)

1. Mizgerd JP. Lung infection—a public health priority. PLoS Med 2006;3:e76.
2. WHO. The World Health Report 2002, no. 2, vol. 16; 2002.
3. Bryce J, Boschi-Pinto C, Shibuya K, Black RE, WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet 2005;365:1147-1152.
4. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-5096.
5. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics 2008;26: 911-924
6. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659-671.
7. Esposito S, Gasparini R, Bosis S, Marchisio P, Tagliabue C et al. Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect 2005;11:933-936.
8. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003;163:487-494.
9. Hsiao C-J, Cherry DK, Beatty PC, Rechtsteiner E A. National ambulatory medical care survey: 2007 summary. Natl Health Stat Report 2010;no. 27:1-32.
10. Turner RB. Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol 1997;78:531-539.
11. Ryu WS, Kang B, Hong J, Hwang S, Kim A et al. Enterovirus 71 infection with central nervous system involvement, South Korea. Emerg Infect Dis 2010;16:1764-1766.
12. Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A et al. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of Enterovirus 71. Microbiol Immunol 2002;46:621-627.
13. Zhang Q, Macdonald NE, Smith JC, Cai K, Yu H et al. Severe enterovirus type 71 nervous system infections in children in the Shanghai region of China: clinical manifestations and implications for prevention and care. Pediatr Infect Dis J 2014;33:482-487.
14. Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther 2011;9:27-32.
15. Patick AK. Rhinovirus chemotherapy. Antiviral Res 2006;71:391-396.
16. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010;9:1097-1105.
17. Kao RY, Yang D, Lau LS, Tsui WH, Hu L et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010; 28:600-605.
18. Bonavia A, Franti M, Pusateri Keaney E, Kuhen K, Seepersaud M et al. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci USA 2011; 108:6739-6744.
19. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. Broadspectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci USA 2011;108:5777-5782.
20. Wachsman M, Hamzeh FM, Assadi NB, Lietman PS. Antiviral activity of inhibitors of pyrimidine de-novo biosynthesis. Antivir Chem Chemother 1996;7:7-13.
21. Lucas-Hourani M, Dauzonne D, Jorda P, Cousin G, Lupan A et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 2013;9:e1003678.
22. Chew T, Noyce R, Collins SE, Hancock MH, Mossman KL. Characterization of the interferon regulatory factor 3-mediated antiviral response in a cell line deficient for IFN production. Mol Immunol 2009;46:393-399.
23. Zheng M, Wang P, Song W, Lau SY, Liu S et al. An A14U substitution in the 3’ noncoding region of the M segment of viral RNA supports replication of influenza virus with an NS1 deletion by modulating alternative splicing of M segment mRNAs. J Virol 2015;89:10273-10285.
24. Chung DH, Golden JE, Adcock RS, Schroeder CE, Chu YK et al. Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferonindependent antiviral state. Antimicrob Agents Chemother 2016;60: 4552-4562.
25. Cheng G, Wang L-CS, Fridlender ZG, Cheng GS, Chen B et al. Pharmacologic activation of the innate immune system to prevent respiratory viral infections. Am J Respir Cell Mol Biol 2010:1-29.
26. Es-Saad S, Tremblay N, Baril M, Lamarre D. Regulators of innate immunity as novel targets for panviral therapeutics. Curr Opin Virol 2012;2:622-628.
27. Smee DF, Hurst BL, Day CW. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 2012;22:263-272.
28. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 2011;85:6548-6556.
29. Smee DF, Mckernan PA, Nord LD, Willis RC, Petrie CR et al. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrob Agents Chemother 1987;31:1535-1541.
30. Smee DF, von Itzstein M, Bhatt B, Tarbet EB. Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs. Antimicrob Agents Chemother 2012;56:6328-6333.
31. Zheng B, Chan K, Lin Y, Zhao G, Chan C et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1. Virus 2008.
32. Wang P, Song W, Mok BW, Zhao P, Qin K et al. Nuclear factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein. J Virol 2009;83:7850-7861.
33. Kok KH, Lui PY, Ng MH, Siu KL, Au SW et al. The double-stranded RNA-binding protein PACT functions as a cellular activator of RIGI to facilitate innate antiviral response. Cell Host Microbe 2011;9: 299-309.